GlassScriptPhysician profile
Alexander Stojanovic
NPI 1225029002
$2,503.08
in general payments reported to CMS, 2019-2025
25 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $188 · 2021: $556 · 2022: $831 · 2023: $242 · 2024: $29.34 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.39 | 2019-2024 | Skyrizi, Mavyret, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $432.75 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $295.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.30 | 2019-2023 | Xifaxan |
| Pfizer INC. | $170.19 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $131.70 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $98.30 | 2022-2023 | Dupixent |
| Celgene Corporation | $91.92 | 2021-2023 | Zeposia |
| Ucb, INC. | $73.50 | 2019 | |
| Qol Medical, LLC | $62.97 | 2019-2022 | |
| Redhill Biopharma INC. | $51.07 | 2021 | |
| Braintree Laboratories, INC. | $37.87 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $28.19 | 2023 | |
| Boston Scientific Corporation | $25.44 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.35 | 2023 | Givlaari |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $23.66 | 2021 | |
| Daiichi Sankyo INC. | $19.55 | 2022 | |
| Solventum Corporation | $19.08 | 2025 | Activ.A.C. |
| Genzyme Corporation | $18.62 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.01 | 2022 | |
| Gilead Sciences, INC. | $15.59 | 2019 | |
| Shionogi INC | $15.57 | 2019 | |
| Capsovision, INC. | $15.36 | 2025 | Capsocam Plus |
| Allergan, INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Stojanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.